Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma

Welcome to OncLive On Air^®! I'm your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive On Air covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In this episode, we spoke with Arndt Vogel, MD, a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre in Canada.

In our exclusive interview, Dr Vogel highlighted the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma, explaining that on-target resistance mutations and the differing binding properties of agents like pemigatinib (Pemazyre), futibatinib (Lytgobi), and the more selective tinengotinib (TT-00420) support using these drugs in sequence, although he emphasized that treatment decisions remain biomarker-informed rather than biomarker-guided. He also stressed the importance of early, RNA-based next-generation sequencing, the emerging role of circulating tumor DNA in capturing polyclonal resistance, and his anticipation of forthcoming phase 3 tinengotinib data.
_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.